The integration of rapid drug resistance detection through enzyme activation into point-of-care testing systems, exemplified by Cheng et al.'s (2022) innovative platform that utilizes allele-specific PCR and lateral flow assays to identify chloroquine resistance in Plasmodium falciparum, significantly enhances clinical diagnostics in resource-limited settings by enabling swift and precise treatment decisions that improve patient management and aid in the control of infectious diseases.